Last $11.90 USD
Change Today -0.09 / -0.75%
Volume 693.8K
AKBA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

akebia therapeutics inc (AKBA) Snapshot

Open
$11.85
Previous Close
$11.99
Day High
$12.43
Day Low
$11.78
52 Week High
06/20/14 - $31.00
52 Week Low
11/10/14 - $8.60
Market Cap
242.1M
Average Volume 10 Days
235.5K
EPS TTM
--
Shares Outstanding
20.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AKEBIA THERAPEUTICS INC (AKBA)

Related News

No related news articles were found.

akebia therapeutics inc (AKBA) Related Businessweek News

No Related Businessweek News Found

akebia therapeutics inc (AKBA) Details

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

24 Employees
Last Reported Date: 03/21/14
Founded in 2007

akebia therapeutics inc (AKBA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $162.0K
Executive Vice President
Total Annual Compensation: $354.0K
Compensation as of Fiscal Year 2013.

akebia therapeutics inc (AKBA) Key Developments

Akebia Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 01:00 PM

Akebia Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 01:00 PM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: John P. Butler, Chief Executive Officer, President and Director.

Akebia Therapeutics, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Akebia Therapeutics, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported operating loss of USD 9,584,000 against USD 4,034,000 a year ago. Net loss applicable to common stockholders was USD 9,348,000 or USD 0.47 per basic and diluted share against USD 6,516,000 or USD 11.92 per basic and diluted share a year ago. The company's cash used in operations during the third quarter of 2014 was USD 5.6 million, an increase of USD 2.7 million from USD 2.9 million for the same period of 2013. For the nine months, the company reported operating loss of USD 27,333,000 against USD 9,732,000 a year ago. Net loss applicable to common stockholders was USD 113,563,000 or USD 8.16 per basic and diluted share against USD 60,081,000 or USD 117.94 per basic and diluted share a year ago.

Akebia Therapeutics, Inc. - Special Call

To discuss positive top-line results from its Phase 2b placebo-controlled trial of AKB-6548

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKBA:US $11.90 USD -0.09

AKBA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKBA.
View Industry Companies
 

Industry Analysis

AKBA

Industry Average

Valuation AKBA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AKEBIA THERAPEUTICS INC, please visit www.akebia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.